GC Biopharma Corp.
Financials
Valuation Metrics
GC Biopharma Corp.'s Market Cap is ₩1.6T. At end of 2025 it was ₩1.9T. Ranked #229 of 2,405 in KR market (top 10%), #180 of 778 on KOSPI (top 23%), #21 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.57T KRW | KR#229/2,405 Sec#21/231 |
| Revenue | 1.96T KRW | KR#261/2,405 Sec#6/231 |
| Net Income | -63.45B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 2.97T KRW | KR#242/2,405 Sec#8/231 |
| Net Assets | 1.39T KRW | KR#228/2,405 Sec#10/231 |
| Employees | 2,355 | KR#124/2,405 Sec#4/231 |
| Value | ||
| P/B | 1.12x | KR#1,614/2,405 Sec#104/231 |
| P/S | 0.80x | KR#1,295/2,405 Sec#72/231 |
| EV/EBITDA | 50.32x | KR#1,359/2,405 Sec#89/231 |
| FCF Yield | 1.73% | KR#1,082/2,405 Sec#72/231 |
| Profitability | ||
| ROE | -4.55% | KR#1,782/2,405 Sec#128/231 |
| ROA | -2.14% | KR#1,760/2,405 Sec#124/231 |
| Op. Margin | 2.41% | KR#1,324/2,405 Sec#95/231 |
| Revenue Growth | 9.73% | KR#909/2,405 Sec#89/231 |
| Earnings Growth | -205.91% | KR#1,237/2,405 Sec#85/231 |
| Financial Health | ||
| Debt Ratio | 113.09% | KR#1,647/2,405 Sec#188/231 |
| Total Debt | 862.25B KRW | KR#226/2,405 Sec#7/231 |
| FCF | 27.10B KRW | KR#439/2,405 Sec#25/231 |
| Cash | 49.37B KRW | KR#743/2,405 Sec#44/231 |
| Current Ratio | 1.35x | KR#1,317/2,405 Sec#139/231 |
| Net Debt/EBITDA | 17.19x | KR#1,344/2,405 Sec#95/231 |
| Dividend | ||
| Div. Yield | 1.12% | KR#1,117/2,405 Sec#63/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | 3.32% | KR#567/2,405 Sec#29/231 |
| 1M Return | 6.52% | KR#147/2,405 Sec#13/231 |
| From 52W High | -27.09% | KR#345/2,405 Sec#21/231 |
| 1Y MDD | -37.22% | KR#467/2,405 Sec#31/231 |
| Trading | ||
| Volume | 28,611 shares | KR#1,309/2,405 Sec#128/231 |
| Trading Value | 3.82B KRW | KR#327/2,405 Sec#29/231 |
| Foreign Own. | 23.82% | KR#177/2,405 Sec#8/231 |
| Per Share | ||
| EPS | -5,429 KRW | KR—/2,405 Sec—/231 |
| BPS | 119,306 KRW | KR#120/2,405 Sec#6/231 |
Company Info
Established in 1969 and headquartered in Yongin-si, Gyeonggi-do, Green Cross is a professional pharmaceutical manufacturer and seller specializing in blood products and vaccine products. Its main businesses include blood products, general products, and vaccine products. The company strengthened its raw plasma procurement capabilities by acquiring US ABO Holdings in 2025 and is entering the global market with ALYGLO's US FDA approval and 2024 launch. Green Cross supplies products to domestic and international markets through its Ochang factory production facilities, aiming to become a global pharmaceutical company focused on key strategic products.